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Abstract
Background: Abnormalities in serum potassium are risk fac-
tors for sudden cardiac death and arrhythmias among dialy-
sis patients. Although a previous study in hemodialysis pa-
tients has shown that race/ethnicity may impact the rela-
tionship between serum potassium and mortality, the 
relationship remains unclear among peritoneal dialysis (PD) 
patients where the dynamics of serum potassium is more 
stable. Methods: Among 17,664 patients who started PD be-
tween January 1, 2007 and December 31, 2011 in a large US 
dialysis organization, we evaluated the association of serum 
potassium levels with all-cause and arrhythmia-related 
deaths across race/ethnicity using time-dependent Cox 
models with adjustments for demographics. We also used 
restricted cubic spline functions for serum potassium levels 
to explore non-linear associations. Results: Baseline serum 
potassium levels were the highest among Hispanics (4.2 ± 
0.7 mEq/L) and lowest among non-Hispanic blacks (4.0 ± 0.7 
mEq/L). Among 2,949 deaths during the follow-up of median 
2.2 (interquartile ranges 1.3–3.2) years, 683 (23%) were ar-
rhythmia-related deaths. Overall, both hyperkalemia and hy-
pokalemia (i.e., serum potassium levels > 5.0 and < 3.5 mEq/L, 
respectively) were associated with higher all-cause and ar-
rhythmia-related mortality. In a stratified analysis according 
to race/ethnicity, the association of hypokalemia with all-
cause and arrhythmia-related mortality was consistent with 
an attenuation for arrhythmia-related mortality in non-His-
panic blacks. Hyperkalemia was associated with all-cause 
and arrhythmia-related mortality in non-Hispanic whites 
and non-Hispanic blacks, but no association was observed in 
Hispanics. Conclusion: Among incident PD patients, hypo-
kalemia was consistently associated with all-cause and ar-
rhythmia-related deaths irrespective of race/ethnicity. How-
ever, while hyperkalemia was associated with both death 
outcomes in non-Hispanic blacks and whites, it was not as-
sociated with either death outcome in Hispanic patients. 
Further studies are needed to demonstrate whether differ-
ent strategies should be followed for the management of 
serum potassium levels according to race/ethnicity. 
© 2019 S. Karger AG, Basel
R.E. and Y.O. equally contributed to the manuscript.
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Introduction
Cardiovascular disease is the leading cause of death 
among dialysis patients [1, 2], where arrhythmia and 
cardiac arrest are some of the major causes of 
 cardiovascular deaths. Abnormalities in serum potas-
sium levels (i.e., hyperkalemia and hypokalemia; or 
dyskalemias) are risk factors for arrhythmias and sud-
den cardiac death [3, 4]. Hypokalemia may lead to ven-
tricular fibrillation [5, 6], while hyperkalemia can lead 
to electromechanical dissociation and asystole [7, 8]. 
Dyskalemias are common among dialysis patients [9, 
10], and both high and low serum potassium levels are 
associated with higher mortality risk [11]. Although 
peritoneal dialysis (PD), when compared to hemodialy-
sis, is less likely to induce myocardial stunning due to 
slower rates of solute clearance and fluid removal [12], 
the prevalence of cardiac arrest and ventricular ar-
rhythmias is actually similar between these 2 dialysis 
modalities [1]. This contradictory consequence may be 
due to lower serum potassium levels among PD pa-
tients [11].
Several studies have examined the impact of race/eth-
nicity on the association of serum potassium levels with 
mortality; however, the findings were inconsistent. One 
study of non-dialysis dependent chronic kidney disease 
(CKD) patients found that hyperkalemia was associated 
with a higher death risk among whites but not among 
African Americans, while hypokalemia was consistently 
associated with mortality in both races [13]. Similarly, a 
later study with over 2 million non-CKD US veterans 
found that mortality risk associated with hyperkalemia 
was lower among African Americans than among non-
African Americans [14]. In maintenance hemodialysis 
patients, however, higher baseline potassium levels were 
associated with higher mortality in both non-Hispanic 
whites and non-Hispanic blacks but not in Hispanics 
[15]. Despite these prior studies, it remains unclear 
whether race/ethnicity modifies the risk associated with 
serum potassium concentrations for all-cause death or 
arrhythmia-related death among PD patients, consider-
ing that potassium kinetics are different among hemodi-
alysis and PD patients. For example, serum potassium 
abruptly decreases during hemodialysis treatment and 
gradually increases thereafter, whereas concentrations 
are more stable among PD patients. We therefore hy-
pothesized that the impact of serum potassium levels on 
mortality is also different according to race/ethnicity 
among PD patients. 
Materials and Methods
The study was approved by the Institutional Review Commit-
tees of the University of California, Irvine and Los Angeles Bio-
medical Research Institute at Harbor-UCLA. Given the large sam-
ple size, anonymity of the patients studied, and nonintrusive nature 
of the research, the requirement for written consent was exempt. 
Patients
We retrospectively analyzed a statistically de-identified data set 
from a large dialysis organization in the United States [16]. We 
analyzed 19,844 patients aged 18 years or older who initiated and 
received PD from one of the facilities operated by the dialysis pro-
vider over a 5-year period (January 1, 2007 to December 31, 2011). 
We excluded 713 patients without available serum potassium data 
while they were treated with PD, and then 1,467 patients of other 
race/ethnicities (767 Asian patients and 700 patients of other rac-
es) than that of non-Hispanic whites, non-Hispanic blacks, and 
Hispanics, resulting in the final analytical cohort of 17,664 inci-
dent PD patients (online suppl. Appendix Fig. S1; for all online 
suppl. material, see www.karger.com/doi/10.1159/000502998). 
Patients were followed from their PD start until the occurrence of 
one of the following events: primary outcome (death), kidney 
transplantation, transfer to another dialysis modality or to a facil-
ity operated by another dialysis provider, or end of administrative 
follow-up (December 31, 2011). 
Demographic, Clinical, and Laboratory Measures
Information on death events, causes of death, race/ethnicity, 
primary insurance, access type, presence of comorbidities, and lab-
oratory variables were obtained from the administrative electron-
ic database of the dialysis provider. The specific causes of death 
code (i.e., hypokalemia, hyperkalemia, cardiac arrhythmia, and 
cardiac arrest) were sourced from data from the large dialysis or-
ganization. Blood samples were drawn in dialysis facilities and 
shipped to a central laboratory, typically within 24 h. All labora-
tory values were measured by automated and standardized meth-
ods. To minimize measurement variability, all repeated measures 
of laboratory variables for each patient were averaged monthly 
from time of PD start. The averaged values during the first month 
after PD start served as baseline data. 
Statistical Analyses
We examined baseline clinical characteristics across race/eth-
nicity as well as according to baseline low (< 3.5 mEq/L: hypokale-
mia), medium (3.5–5.0 mEq/L: normal), and high (> 5.0 mEq/L: 
hyperkalemia) serum potassium levels within each race/ethnicity 
group. Data are presented as means (± SD) or medians (interquar-
tile ranges), or proportions, where appropriate. 
The exposure of interest was monthly averaged serum potas-
sium levels. Between 70 and 80% of monthly averaged potassium 
values were derived from only one measurement (online suppl. 
Appendix Fig. S2). The primary outcome of interest was all-cause 
mortality. The secondary outcome was the composite outcome of 
arrhythmia-related deaths or those potentially related to dyskale-
mias (i.e., deaths due to hypokalemia, hyperkalemia, cardiac ar-
rhythmia, and cardiac arrest). As a sensitivity analysis, we also ex-
amined associations with any cardiac death (i.e., myocardial in-
farction, pericarditis, atherosclerotic heart disease, cardiomyopathy, 
cardiac arrhythmia, cardiac arrest, valvular heart disease, pulmo-
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nary edema, and congestive heart disease). Moreover, we also ex-
amined the association of the highest and lowest measured potas-
sium levels of each month with mortality because the use of 
monthly averaged values may bias estimates toward the null if se-
rial serum potassium levels were measured after the intervention 
against dyskalemias.
We used time-dependent Cox models to examine the short-
term association between serum potassium levels and mortality. 
Monthly averaged serum potassium levels were modeled as con-
tinuous variables, and the non-linear relationship with each out-
come was estimated using restricted cubic spline functions with 4 
knots at the 5th, 35th, 65th, and 95th percentiles of observed values 
and using serum potassium 4.0 mEq/L as a reference. We also used 
post estimation to calculate predicted hazard ratios at serum potas-
sium levels of 2.5, 3.0, 3.5, 4.5, 5.0, 5.5, 6.0, 6.5, and 7.0 mEq/L us-
ing 4.0 mEq/L as a reference. We employed 3 levels of hierarchical 
adjustment: (1) unadjusted model, (2) case-mix adjusted model 
that included age, sex, race/ethnicity, diabetes mellitus, and pri-
mary insurance at baseline as well as the preexisting comorbidities 
(hypertension, atherosclerotic heart disease, congestive heart fail-
ure, and other cardiovascular disease), and (3) case-mix and mal-
nutrition-inflammation cachexia syndrome (MICS) adjusted 
model that included all above-mentioned covariates and time-up-
dated data on 7 surrogates of nutritional and inflammatory status; 
body mass index, hemoglobin, and serum levels of albumin, cre-
atinine, calcium, phosphorus, and bicarbonate. We used log-like-
lihood ratio tests to formally assess the interaction between time 
varying serum potassium and race ethnicity with mortality. 
For evaluating differences in hazard ratios across race/ethnic-
ity, we evaluated the association under the unadjusted and case-
mix adjusted models as our primary model due to potential over 
adjustment with MICS variables because of the limited number of 
events. However, in sensitivity analysis, we also evaluated associa-
tions with the case-mix model and additional adjustment for se-
rum creatinine, Kt/V, and residual renal function (RRF). Missing 
covariate data at baseline and during the follow-up period were 
imputed using the mean of within-individual values measured 
within ± 1 month, or using the last-observation carried forward 
method if no data were available during ± 1 month. Missing fre-
quencies at baseline (i.e., the first month) and during the first 
2 months (i.e., the first and second month) were < 10 and < 1% for 
hemoglobin, serum albumin, calcium, and phosphorus; 15 and 
1.5% for serum creatinine and bicarbonate; and 50 and 19% for 
body mass index, respectively. We also conducted sensitivity anal-
yses after restricting the study population to 16,004 patients with 
available data on baseline (i.e., the first month from PD start) se-
rum potassium. All analyses were carried out using STATA MP 
version 13.1 (StataCorp., College Station, TX, USA).
Results
Baseline Demographic, Clinical, and Laboratory 
Characteristics According to Baseline Serum 
Potassium Level Across Race/Ethnicity
Among 17,664 patients, the mean ± SD age was 56 ± 
16 years; 44% were female; 62% were non-Hispanic white, 
25% were non-Hispanic black, and 14% were Hispanic; 
and 62% had diabetes as the cause of end-stage renal dis-
ease (Table 1). Baseline serum potassium levels were the 
highest among Hispanics (4.2 ± 0.7 mEq/L) and lowest 
among non-Hispanic blacks (4.0 ± 0.7 mEq/L; p < 0.001). 
The prevalence of hyper- and hypokalemia (i.e., serum 
potassium levels > 5.0 and < 3.5 mEq/L) was 9 and 15% 
among non-Hispanic whites, 8 and 20% among non-His-
panic blacks, and 12 and 13% among Hispanics respec-
tively (online suppl. Appendix Table 1). Those who had 
lower serum potassium levels in all races were more like-
ly to be older, female; have higher bicarbonate; and have 
lower serum albumin, creatinine, and phosphorus.
Association of Monthly-Averaged Serum  
Potassium Levels with All-Cause Mortality and 
Arrhythmia-Related Mortality in the Entire Cohort
A total of 2,949 deaths, including 683 arrhythmia-re-
lated deaths (90% of which were coded as cardiac arrest), 
were observed during the follow-up period (up to 5 years; 
median 2.2 [interquartile ranges 1.3–3.2] years). In spline 
models, lower serum potassium was associated with high-
er risk of all-cause and arrhythmia-related death across all 
levels of adjustment, while associations of higher serum 
potassium with higher risk of both death outcomes at-
tenuated towards the null with model adjustment (Fig. 1). 
In the unadjusted model, both hyperkalemia and hy-
pokalemia were associated with higher all-cause mortal-
ity compared with the referent value (4.0 mEq/L; Fig. 1a). 
These findings were consistent in the primary model (i.e., 
the case-mix adjusted model) with hazard ratios (HRs; 
95% CI) of 4.16 (3.40–5.08), 1.41 (1.35–1.47), 1.15 (1.06–
1.25), and 1.65 (1.41–1.93) at serum potassium levels of 
2.5, 3.5, 5.0, and 6.0 mEq/L (vs. 4.0 mEq/L) respectively 
(Fig. 1b). Further adjustment for nutritional and inflam-
matory surrogates (i.e., the case-mix and MICS model) 
attenuated these associations, but the association of hy-
pokalemia with all-cause mortality remained similar; 
HRs (95% CI) were 2.20 (1.66–2.93), 1.64 (1.39–1.94), 
and 1.22 (1.15–1.30) at serum potassium level of 2.5, 3.0, 
and 3.5 mEq/L respectively (Fig. 1c). Associations of hy-
perkalemia with all-cause mortality were attenuated in 
the case-mix and MICS model.
Serum potassium levels showed a similar pattern in its 
associations with arrhythmia-related mortality (vs. all-
cause mortality; Fig. 1d–f). Case-mix adjusted HRs (95% 
CI) were 4.43 (2.95–6.66), 1.39 (1.28–1.52), 1.23 (1.03–
1.46), and 1.64 (1.18–2.27) at serum potassium level of 
2.5, 3.5, 5.0 and 6.0 mEq/L respectively (Fig. 1e). Further 
adjustment for nutritional and inflammatory surrogates 
(i.e., the case-mix and MICS model) attenuated these as-
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sociations, but the association of hypokalemia with ar-
rhythmia-related mortality remained significant; HRs 
(95% CI) were 2.36 (1.31–4.24), 1.70 (1.21–2.40), and 1.24 
(1.09–1.40) at serum potassium level of 2.5, 3.0, and 
3.5 mEq/L respectively (Fig. 1f). Associations of hyperka-
lemia with arrhythmia-related mortality were attenuated 
in the case-mix and MICS model.
Association of Monthly-Averaged Serum Potassium 
Levels with All-Cause Mortality Across Race/Ethnicity
During the follow-up period, 2,216, 488, and 245 all-
cause deaths were observed among non-Hispanic white, 
non-Hispanic black, and Hispanic patients, respectively. 
Among non-Hispanic white patients, serum potassium 
levels showed a U-shaped association with higher all-
cause mortality (case-mix adjusted HRs, 4.98 [3.88–6.40], 
1.47 [1.40–1.55], 1.17 [1.06–1.30], and 1.79 [1.49–2.14] at 
2.5, 3.5, 5.0, and 6.0 mEq/L [referent, 4.0 mEq/L], respec-
tively; Fig. 2a). A slightly attenuated but consistent asso-
ciation was observed among non-Hispanic black patients 
with case-mix adjusted HRs of 2.50 (1.57–3.97), 1.19 
(1.07–1.31), 1.27 (1.02–1.57), and 1.37 (1.01–1.85) at 2.5, 
3.5, 5.0, and 5.5 mEq/L, respectively (Fig.  2b). Among 
Hispanic patients, lower serum potassium levels were 
consistently associated with higher all-cause mortality, 
but the mortality risk was not elevated at higher serum 
potassium levels (case-mix adjusted HRs, 5.37 [2.97–
9.73], 2.84 [2.01–4.00], and 1.51 [1.32–1.73] at 2.5, 3.0, 
and 3.5 mEq/L, respectively; Fig. 2c). Under the case-mix, 
serum creatinine, Kt/V, and RRF adjusted model, the as-
sociation estimates were modestly attenuated, but showed 
a similar pattern to the main results (online suppl. Ap-
pendix Fig. S3). Log likelihood tests demonstrated sig-
nificant interactions between race-ethnicity and serum 
potassium for mortality outcomes (case-mix adjusted 
model [p < 0.001], case-mix and MICS model [p = 0.035]).
Table 1. Baseline characteristics stratified race/ethnicity in 17,664 incident PD patients
Variable Overall Race-ethnicity
non-hispanic white non-hispanic black hispanic
Patient number 17,664 10,923 4,360 2,381
Age, years 56±16 60±15 51±14 51±16
Gender, female, % 44 40 52 44
DM, % 62 60 62 70
Primary insurance, %
Medicare 47 49 42 44
Medicaid 4 3 4 11
Others 49 48 54 45
Comorbidities, %
Hypertension 53 50 63 47
CHF 20 19 22 18
ASHD 17 19 14 13
Other cardiac disease 15 16 12 12
Baseline BMI, kg/m2 28 (24–32) 28 (24–32) 29 (24–34) 28 (24–32)
Baseline laboratory tests
Potassium, mEq/L 4.1±0.7 4.1±0.7 4.0±0.7 4.2±0.7
WBC, 1,000/μL 7.0 (5.7–8.7) 7.3 (5.9–8.9) 6.4 (5.1–7.9) 7.1 (5.9–8.9)
Hemoglobin, g/dL 11.6±1.5 11.7±1.5 11.4±1.6 11.7±1.6
Albumin, g/dL 3.7±0.5 3.7±0.5 3.7±0.5 3.7±0.6
Creatinine, mg/dL 7.1±3.6 6.3±3.1 8.6±4.3 7.6±3.8
Calcium, mg/dL 8.8±0.8 8.9±0.7 8.8±0.8 8.6±0.8
Phosphorus, mg/dL 5.0±1.5 5.0±1.5 5.0±1.5 5.1±1.5
Bicarbonate, mEq/L 25.2±3.5 25.5±3.5 25.0±3.5 24.7±3.5
Continuous values are expressed as mean ± SD or median (interquartile range) as appropriate. 
Missing frequency at consecutive months (month 1 and 2) was 1.5% for serum creatinine, 8.1% for BMI, and <1% for hemoglobin, 
serum albumin, calcium, phosphorus, and bicarbonate.
PD, peritoneal dialysis; DM, diabetes mellitus; CHF, congestive heart failure; ASHD, atherosclerotic heart disease; BMI, body mass 
index; WBC, white blood cell. 
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Association of Monthly-Averaged Serum Potassium 
Levels with Arrhythmia-Related Mortality Across 
Race/Ethnicity
During the follow-up period, 486, 116, and 81 arrhyth-
mia-related deaths were observed among non-Hispanic 
white, non-Hispanic black, and Hispanic patients respec-
tively. Consistent findings were obtained for arrhythmia-
related death as compared to all-cause death (Fig.  3). 
Higher serum potassium levels were associated with 
higher arrhythmia-related mortality among non-Hispan-
ic white and non-Hispanic black patients but not among 
Hispanic patients. The association between hypokalemia 
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Fig. 1. Distribution of baseline serum potassium levels and the as-
sociation of monthly averaged serum potassium levels with (a–c) 
all-cause mortality and (d–f) arrhythmia-related mortality with 3 
levels of adjustment (unadjusted, case-mix adjusted, and case-mix 
and MICS adjusted). Dashed and solid lines represent HRs esti-
mates and 95% CIs, respectively. HR, hazard ratios.
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< 3.5 mEq/L and arrhythmia-related mortality appeared 
consistent across race/ethnicity although it was attenu-
ated for non-Hispanic black patients, possibly due to a 
limited number of events. The association of serum po-
tassium levels with arrhythmia-related mortality across 
race/ethnicity was modestly attenuated under case-mix, 
serum creatinine, Kt/V, and RRF adjustments, however, 
the relationships were consistent (online suppl. Appendix 
Fig. S4). We also observed a consistent race/ethnic differ-
ence in the association of serum potassium levels with 
cardiac death (online suppl. Appendix Fig. S5). 
Using the highest and lowest serum potassium levels 
as exposures, we also observed consistent results across 
race/ethnicity. Sensitivity analyses after restricting the 
study population to 16,004 patients with available serum 
potassium data at baseline (i.e., the first month from PD 
start) also showed consistent results.
Discussion
In this longitudinal national cohort of 17,664 incident 
PD patients, we demonstrated that lower serum potassi-
um levels < 3.5 mEq/L were consistently associated with 
higher all-cause and arrhythmia-related deaths across 
race/ethnicity. On the other hand, higher serum potassi-
um levels > 5.0 mEq/L were associated with all-cause and 
arrhythmia-related death among non-Hispanic whites 
and blacks but not among Hispanic patients. To our 
knowledge, this is the first study to examine the differ-
ences in the impact of serum potassium levels on mortal-
ity across racial/ethnic groups among PD patients using 
a time-dependent model. 
Hypokalemia was a risk factor for all-cause death among 
PD patients in our study. Short-term associations with 
mortality, as indicated by the time-dependent model, could 
b c
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Fig. 2. Distribution of baseline serum potassium levels and the as-
sociation of monthly averaged serum potassium levels with all-
cause mortality across race/ethnicity in the case-mix adjusted 
model; (a) non-Hispanic white, (b) non-Hispanic black, and (c) 
Hispanic patients. Dashed and solid lines represent HRs estimates 
and 95% CIs respectively. HR, hazard ratios.
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be partly explained by the impact of potassium on ventric-
ular arrhythmogenicity [17, 18]. Indeed, we confirmed the 
association with arrhythmia-related death even after ad-
justing for various nutritional and inflammatory markers. 
Other potential factors contributing to a hypokalemia-
mortality association include predisposition to stroke [19] 
and respiratory muscle weakness [20], but there still may 
be residual confounding with MICS [11], given the correla-
tion between oral intakes of potassium and protein. 
In this study, serum potassium levels were the lowest 
among non-Hispanic blacks and the highest among His-
panics, with non-Hispanic whites in the middle. This ten-
dency was also observed in previous studies among 
healthy adults [14] and hemodialysis patients [15]. It has 
been shown that dietary intake and urinary excretion of 
potassium are different according to race/ethnicity [21, 
22]. For example, non-Hispanic black patients consume 
a lower potassium diet [23] and have significantly lower 
urinary potassium excretion [24–27]. Although serum 
potassium level has a poor correlation with dietary potas-
sium intake in the dialysis population [28, 29], residual 
kidney function among PD patients may still play a role 
in the difference in serum potassium levels; the lower uri-
nary excretion of potassium in blacks seemed to be inde-
pendent of dietary differences in the Dietary Approaches 
to Stop Hypertension trial [27]. Other possible explana-
tions for the differences in potassium dynamics among 
non-Hispanic blacks include (1) increased activity of the 
Na-K-2Cl cotransporter in the thick ascending limb of 
the loop of Henle [24], (2) increased fecal excretion of 
potassium [30], and (3) differences in cellular potassium 
disposal [25]. Gastrointestinal absorption [31] or aldoste-
rone excretion [32] may also be related to racial differ-
ences in serum potassium levels. 
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Fig. 3. Distribution of baseline serum potassium levels and the as-
sociation of monthly averaged serum potassium levels with ar-
rhythmia-related mortality across race/ethnicity in the case-mix 
adjusted model; (a) non-Hispanic white, (b) non-Hispanic black, 
and (c) Hispanic patients. Dashed and solid lines represent HRs 
estimates and 95% CIs respectively. HR, hazard ratios.
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We found a racial/ethnic difference in the impact of hy-
perkalemia on all-cause and arrhythmia-related mortality 
among PD patients. One possible explanation is the differ-
ence in the trajectories of serum potassium levels before 
developing hyperkalemia across race/ethnicity. Chronic 
hyperkalemia is reported to be better tolerated than an 
acute rise, and patients with CKD who chronically increase 
their serum potassium levels can present with no apparent 
electrocardiographic or cardiovascular manifestations 
even in the range of > 6.0 mEq/L [33–35]. The highest base-
line serum potassium levels among Hispanic PD patients 
indicates the more chronic nature of hyperkalemia after 
dialysis initiation than the other groups, which might have 
led to tolerance against hyperkalemia. Another potential 
mechanism for the racial/ethnic difference in the hyperka-
lemia-mortality association is the racial/ethnic difference 
in cardiac potassium channel variants that may be related 
to susceptibility against dyskalemia [36]. In contrast to the 
association between hyperkalemia and mortality, howev-
er, our study in PD patients suggested that lower potassium 
levels were consistently associated with all-cause and ar-
rhythmia-related death across race/ethnicity. Some recent 
studies showed that a greater fruit and vegetable intake was 
associated with improving cardiovascular disease risk in-
dicators among patients with CKD [37], and lower all-
cause and non-cardiovascular death among maintenance 
hemodialysis patients [38]. Hispanics may be good candi-
dates for liberalizing potassium intake, which requires fu-
ture investigation.
Several limitations of our study should be noted. First, 
given the nature of an observational cohort analysis, there 
may be residual confounding or unmeasured confound-
ers. Second, the small numbers of outcome events might 
have limited our ability to detect the arrhythmia-mortal-
ity association. However, it should be noted that the esti-
mated HRs for both all-cause and arrhythmia-related 
death at higher serum potassium levels were lower than 
1.0 among Hispanic patients. Third, information on the 
cause of death was recorded by the LDO and we cannot 
ascertain its accuracy and precision. The majority of ar-
rhythmia-related deaths were due cardiac arrest, which 
does not differentiate between bradycardia and tachycar-
dia. Cardiac arrest in arrhythmia-related or cardiac death 
may include the other situations that are not related with 
abnormal serum potassium levels while arrhythmia-re-
lated or cardiac deaths might have been categorized as 
other causes of death. Additionally, very few patients had 
hypokalemia and hyperkalemia listed as the specific cause 
of death and we therefore could not separately evaluate 
associations with these more specific directional causes of 
death. Further studies are needed to examine these rela-
tionships. Fourth, we did not have precise data on medi-
cations which could have influenced serum potassium 
levels and all-cause or arrhythmia-related death. 
In conclusion, our study demonstrated that among in-
cident PD patients, hypokalemia was consistently associ-
ated with all-cause and arrhythmia-related deaths irre-
spective of race/ethnicity while hyperkalemia was not as-
sociated with either mortality outcome in Hispanics. 
Further studies are needed to demonstrate whether dif-
ferent strategies should be followed in the management 
of serum potassium levels according to race/ethnicity.
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